Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Narnatumab, an antibody targeting MST1R.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Flanvotumab, an antibody targeting TYRP1.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Perakizumab, an antibody targeting IL-17A.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Nesvacumab, an antibody targeting ANGPT2.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Enoticumab, an antibody targeting DLL4.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Demcizumab, an antibody targeting DLL4.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Vantictumab, an antibody targeting FZD.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Sofituzumab, an antibody targeting MUC16.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Ralpancizumab, an antibody targeting PCSK9.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Vandortuzumab, an antibody targeting STEAP1.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Pasotuxizumab, an antibody targeting PSMA × CD3E.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Brontictuzumab, an antibody targeting NOTCH1.